Integrative Sciences and Engineering Programme (ISEP), NUS Graduate School (NUSGS), National University of Singapore, Singapore, Singapore.
Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Med Res Rev. 2022 Sep;42(5):1739-1780. doi: 10.1002/med.21891. Epub 2022 May 20.
Zika virus (ZIKV) is an arbovirus belonging to the flavivirus genus and is transmitted in Aedes mosquito vectors. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia. Patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. However, severe infections may have neurological implications, such as Guillain-Barré syndrome and fetal microcephaly. To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments mainly target the symptoms of infection. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Hence, this paper will review recent advances in natural products in ZIKV antiviral drug discovery.
Zika 病毒（ZIKV）是一种黄病毒属的虫媒病毒，通过埃及伊蚊传播。自 1952 年在乌干达首次在人类中发现以来，ZIKV 已在南美洲、非洲和亚洲引发了多次暴发。感染 ZIKV 的患者通常无症状；轻症包括发热、关节和肌肉疼痛以及疲劳。然而，严重感染可能会对神经系统产生影响，例如吉兰-巴雷综合征和胎儿小头畸形。迄今为止，尚无针对 ZIKV 感染的已批准的治疗性药物或疫苗；治疗主要针对感染的症状。预防蚊虫滋生是限制病毒传播的主要策略。针对 ZIKV 感染的抗病毒药物研究正在迅速发展，药物重定位研究和化合物筛选涌现出许多候选药物。特别是，一些研究表明天然产物具有抗 ZIKV 感染的潜力。因此，本文将综述天然产物在 ZIKV 抗病毒药物发现方面的最新进展。
